版本:
中国

BRIEF-Novartis says drug combination Tafinlar + Mekinist receives EU approval

April 3 Novartis Ag

* Novartis drug combination Tafinlar + Mekinist receives EU approval for BRAF v600-positive advanced non-small cell lung cancer (NSCLC) Source text for Eikon: [here ] Further company coverage: (Reporting by Zurich Newsroom)

我们的标准: 汤森路透“信任原则

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐